Table 2.

Meta‐analyses of reduction from baseline in primary seizures and ≥50% responder rates for LGS populations, overall and on clobazam (intention‐to‐treat population)

Trial	Treatment arm vs placebo	Overall			On clobazam
		Interaction p‐value	Treatment/odds ratio a (95% CI)	p‐value	Interaction p‐value	Treatment/odds ratio a (95% CI)	p‐value
Reduction in drop seizure frequency
GWPCARE3	CBD10		0.71 (0.56‐0.89)	0.0032	0.9727	0.70 (0.51‐0.98)	0.0355
	CBD20		0.66 (0.53‐0.83)	0.0005	0.0067	0.46 (0.33‐0.64)	<0.0001
GWPCARE4	CBD20		0.73 (0.59‐0.90)	0.0036	0.0123	0.54 (0.40‐0.73)	<0.0001
Meta‐analysis	CBD10 + CBD20	0.8244	0.70 (0.62‐0.80)	<0.0001	0.1948	0.56 (0.47‐0.67)	<0.0001
	CBD20	0.5363	0.70 (0.60‐0.82)	<0.0001	0.4734	0.51 (0.41‐0.63)	<0.0001
≥50% responder rate
GWPCARE3	CBD10		3.30 (1.48‐7.35)	0.0035	0.5021	2.72 (0.96‐7.67)	0.0584
	CBD20		3.87 (1.76‐8.53)	0.0008	0.7015	5.12 (1.81‐14.54)	0.0021
GWPCARE4	CBD20		2.61 (1.35‐5.06)	0.0044	0.6190	3.14 (1.26‐7.81)	0.0140
Meta‐analysis	CBD10 + CBD20	0.7482	3.14 (2.04‐4.81)	<0.0001	0.6720	3.48 (1.96‐6.17)	<0.0001
	CBD20	0.4545	3.07 (1.85‐5.10)	<0.0001	0.4879	3.88 (1.95‐7.71)	<0.0001

Results are based on a fixed‐effects meta‐analysis. The interaction p‐value tested the null hypothesis of homogeneity of the treatment effect across trials/dose comparisons.

Abbreviations: CBD10, cannabidiol 10 mg/kg/day; CBD20, cannabidiol 20 mg/kg/day; CI, confidence interval; LGS, Lennox–Gastaut syndrome.

^aReductions in drop seizure frequency are displayed using treatment ratios; ≥50% responder rates are displayed using odds ratios.